NCT06784752 2026-04-16
NETTER-3
Novartis
Phase 3 Recruiting
Clinical Trials
11 trialsNCT06881992 2026-04-14
Tumor HI
Rezolute
Phase 3 Recruiting
NCT00569127 2026-04-13
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03375320 2026-04-13
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03049189 2026-04-06
COMPETE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT05477576 2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT07087054 2026-03-10
CAREFNDR
Crinetics Pharmaceuticals Inc.
Phase 3 Recruiting
NCT04810091 2026-03-09
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT05918302 2026-03-06
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT04706910 2026-02-09
18F-DOPA II - PET Imaging Optimization
University of Alberta
Phase 3 Recruiting
NCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting